LCT expands diabetes trial

By Dylan Bushell-Embling
Friday, 06 June, 2008

Living Cell Technologies (ASX: LCT) has decided to begin testing larger doses in its phase 1 clinical trial for type 1 diabetes.

In phase one of the trial, five patients were implanted with the lowest recommended dose of the company's DiabeCells, encapsulated insulin-producing cells sourced from pigs.

So far the patients have experienced no ill-effects, and have experienced a quantifiable reduction in the amount of insulin they require daily.

Both the number of patients and the dosage they receive has been doubled over the previous trial, with 10 patients receiving the double dose.

Related News

SEQ koala population carries immunity to retrovirus

Koalas from a population north of the Brisbane River appear to have evolved a unique genomic...

RSV immunisation program for babies slashes hospital stays

An Australian-first study has demonstrated the effectiveness of immunisation against respiratory...

A targeted treatment option for psoriasis

New research from MedUni Vienna paves the way for the development of a therapy that not only...


  • All content Copyright © 2025 Westwick-Farrow Pty Ltd